Shannon Steinhauser
Optometrist · Phoenix, AZNPI 1447255310
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 35.2% of the total. Reporting peaked in 2020 at $3,570 and has fallen 86.6% since, to $479 in 2025. Among optometrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $67.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- Bausch & Lomb Americas Inc.$3K
- Novartis$955
- Sun Pharmaceutical Industries Inc.$739
- Alcon$590
- Sight Sciences, Inc.$448
- plus $2K from 20 others
What the payments were for
- Consulting fees$4,00032%
- Speaking & faculty fees$2,43819%
- Food & beverage$6,09149%
- Entertainment$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $4,423 |
| Bausch & Lomb Americas Inc. | 25 | $3,053 |
| Novartis | 25 | $955 |
| Sun Pharmaceutical Industries Inc. | 31 | $739 |
| Alcon | 13 | $590 |
| Sight Sciences, Inc. | 8 | $448 |
| Tarsus Pharmaceuticals, Inc. | 10 | $386 |
| Glaukos Corporation | 5 | $321 |
| Dompe US, Inc. | 8 | $209 |
| Coopervision Inc. | 7 | $205 |
| Thea Pharma Inc. | 1 | $186 |
| Astellas Pharma US Inc | 3 | $162 |
| Oyster Point Pharma, Inc. | 5 | $150 |
| Kala Pharmaceuticals, Inc. | 6 | $135 |
| Tearlab Corp | 2 | $108 |
| ANI Pharmaceuticals, Inc. | 4 | $90 |
| Shire North American Group Inc | 5 | $89 |
| Biotissue Holdings Inc. | 4 | $62 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $58 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| AbbVie | 1 | $33 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| The Walman Optical Company | 1 | $24 |
| Maculogix, Inc. | 1 | $22 |
| Optos, Inc. | 1 | $19 |
| Akorn Operating Company LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$6,556
- XIIDRA$461
- SIMBRINZA$151
- ILUX$125
- XDEMVY$122
- LOTEMAX SM$120
- Izervay$117
- KXL System$116
- TearCare$106
How this compares
$12,548 in reported general payments places this provider in the 95th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 36 | $15,560 |
| VyzultaLatanoprostene Bunod | 31 | $10,611 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $6,910 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $6,712 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,998 |
| Latanoprost | 64 | $356 |
| Timolol Maleate | 24 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $33 | $15,56036 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $3,053 | $10,61131 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $25 | $6,91020 claims |
| AlconSimbrinza | $590 | $6,71227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Phoenix
- Debbie DuongPhoenix$14K
- Simon ZmyslinskiPhoenix$12K
- Ric RiosPhoenix$12K
- Stephanie MastoresPhoenix$11K
- Allissun HoppertPhoenix$10K
- Keyla GammaranoPhoenix$10K
- Randall PaulPhoenix$10K
- Amanda MisincoPhoenix$8K
- Amy CzyzPhoenix$8K
- Rachel DickertPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.